Aldeyra Therapeutics is a biotechnology company focused on developing and commercializing innovative therapies to treat immune-mediated and metabolic diseases
The company is particularly known for its research in ocular disorders and rare diseases, utilizing its proprietary platform to create novel compounds that aim to modulate immune responses and address unmet medical needs. Aldeyra is committed to advancing its therapeutic pipeline through clinical trials, bringing potential new treatment options to patients facing debilitating health conditions.
Aldeyra Therapeutics announces successful results from its Phase 3 clinical trial of reproxalap. The results support a potential 2024 NDA resubmission.
The Dow Jones index closed lower by around 0.1% on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
U.S. stocks traded higher toward the end of trading, with the S&P 500 gaining over 1% on Monday. The Dow traded up 0.93% to 33,983.22 while the NASDAQ rose 1.31% to 13,582.67. The S&P 500 also rose, gaining, 1.11% to 4,375.72.
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 100 points on Monday. The Dow traded up 1.02% to 34,012.79 while the NASDAQ rose 1% to 13,541.79. The S&P 500 also rose, gaining, 1.03% to 4,372.52.
U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 200 points on Monday. The Dow traded up 0.72% to 33,913.22 while the NASDAQ rose 0.46% to 13,468.82. The S&P 500 also rose, gaining, 0.60% to 4,353.60.
Aldeyra Therapeutics Inc (NASDAQALDX) shares are trading lower by 62% to $2.07 during Monday's pre-market session. The company on Monday morning received feedback from the U.S.
Aldeyra Therapeutics Inc (NASDAQALDX) announced top-line results from the Phase 2 clinical trial of ADX‑629, an investigational new drug administered orally to
